Managers / Q2 2024 · view latest →
Vida Ventures Advisors, LLC
CIK 0001831423 · 40 BROAD STREET, SUITE 201, BOSTON, MA, 02109 · 6176489100
Summary
Vida Ventures Advisors, LLC reported $91M in U.S.-listed holdings across 5 positions for Q2 2024.
The portfolio is heavily concentrated: 260 alone accounts for 38.8% of reported value.
The book was largely unchanged from Q1 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 61.2% · $56M
- ADR · 38.8% · $36M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KYTXKyverna Therapeutics, Inc. | HELD | +0 | 4.52M | −$78M | $34M |
| 260Centessa Pharmaceuticals plc | HELD | +0 | 3.93M | −$9M | $36M |
| ALLOAllogene Therapeutics, Inc. | HELD | +0 | 1.80M | −$4M | $4M |
| DYNDyne Therapeutics, Inc. | HELD | +0 | 407.5K | +$3M | $14M |
| KRON1USDKronos Bio, Inc. | HELD | +0 | 2.77M | −$165,919 | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | 260Centessa Pharmaceuticals plchistory → | Ordinary Shares | 38.83% | $36M | 3.93M |
| 2 | KYTXKyverna Therapeutics, Inc.history → | Common Stock | 37.11% | $34M | 4.52M |
| 3 | DYNDyne Therapeutics, Inc.history → | Common Stock | 15.73% | $14M | 407.5K |
| 4 | ALLOAllogene Therapeutics, Inc.history → | Common Stock | 4.58% | $4M | 1.80M |
| 5 | KRON1USDKronos Bio, Inc.history → | Common Stock | 3.75% | $3M | 2.77M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $29M | 2 | Nov 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $16M | 2 | Jul 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $14M | 3 | Apr 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $146M | 6 | Jan 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $139M | 6 | Oct 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $91M | 5 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $180M | 5 | Apr 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $84M | 7 | Jan 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $65M | 8 | Oct 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $77M | 7 | Jul 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $73M | 7 | Apr 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $74M | 7 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $111M | 8 | Oct 5, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $118M | 8 | Jul 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $172M | 8 | May 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $267M | 8 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $349M | 8 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $399M | 9 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $396M | 8 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $487M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $160M | 5 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.